Catalent Appoints Two Executives to Board of Directors - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Appoints Two Executives to Board of Directors


Catalent, Inc. has announced that it made two appointments to its board of directors.

Jack Stahl was president and chief executive officer of Revlon, Inc. between 2002 and 2006. Previously, he acted as president and chief operating officer of The Coca-Cola Company from 2000 to 2001. Stahl also serves on the boards of Coty, Inc., Delhaize Group, and the US Board of Advisors of CVC Capital. Additionally, he formerly served on the boards of Schering-Plough Corporation and Dr. Pepper Snapple Group. He holds a bachelor’s degree in economics from Emory University and a Master’s degree from the Wharton School of Business at the University of Pennsylvania.

Rolf Classon was chairman of the executive committee at Bayer HealthCare AG, a subsidiary of Bayer AG, from October 2002 until his retirement in July 2004. He served as president of Bayer Diagnostics from 1995 to 2002 and as executive vice president from 1991 to 1995. Prior to 1991, Classon held various management positions with Pharmacia Corporation. He currently serves as chairman of the Boards of Auxilium Pharmaceuticals, Inc., Hill-Rom Corporation, and Tecan Group Ltd., and he serves on the board of Fresenius Medical Care. Mr. Classon served as vice chairman of Auxilium Pharmaceuticals, Inc. from March 2005 to April 2005, and he was interim chief executive officer of Hill-Rom Corporation from May 2005 until March 2006. Classon also served as a director on the boards of Millipore Corporation, Prometheus Laboratories Inc., and Enzon Pharmaceuticals, Inc. Classon received a chemical engineering certificate from the Gothenburg School of Engineering and a business degree from the Gothenburg University

Stahl and Classon have also joined Catalent’s audit committee, with Stahl serving as Chair.

Source: Catalent Inc.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here